Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Wuxi Biologics (Cayman) ( (HK:2269) ) just unveiled an announcement.
WuXi Biologics announced that substantial shareholder WuXi Biologics Holdings Limited has agreed to sell 150 million existing shares, or about 3.63% of the company’s issued share capital, via a block trade arranged by Morgan Stanley at HK$38.52 per share to independent investors. Following completion, WuXi Biologics Holdings’ stake will fall from roughly 12.12% to 8.49%, meaning it will no longer qualify as a substantial shareholder, while it has also agreed to a 90-day lock-up on further disposals, a move that reshapes the company’s shareholding structure and may influence investor perceptions of control and future share liquidity.
The most recent analyst rating on (HK:2269) stock is a Buy with a HK$37.36 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
WuXi Biologics (Cayman) Inc. is a Hong Kong-listed biologics company that provides end-to-end contract development and manufacturing services for biopharmaceutical products. The company operates as a key outsourcing partner for global pharmaceutical and biotech firms, supporting the development and production of biologic drugs across international markets.
Average Trading Volume: 30,840,976
Technical Sentiment Signal: Buy
Current Market Cap: HK$165.3B
For an in-depth examination of 2269 stock, go to TipRanks’ Overview page.